iCAD to Report Second Quarter 2021 Financial Results on Thursday, August 5
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iCAD, a leader in cancer detection and therapy solutions, announced it will release its financial results for Q2 and six-months ending June 30, 2021, on August 5, 2021, after market close. This will be followed by a conference call at 4:30 PM ET. The call aims to discuss performance metrics, offering insights into the company’s financial health and strategic direction. Investors are encouraged to join the call to gain a comprehensive understanding of iCAD's progress and outlook.
Positive
- Scheduled conference call for Q2 results indicates transparency and investor engagement.
Negative
- None.
Details
News Market Reaction – ICAD
The recorded move for ICAD in the trading session of this news was -3.17%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHUA, N.H., July 22, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, August 5.
| Thursday, August 5th @ 4:30pm ET | |
| Domestic: | 888-254-3590 |
| International: | 323-994-2082 |
| Conference ID: | 6177004 |
| Webcast: | http://public.viavid.com/index.php?id=145901 |
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com
Investor Relations:
Jeremy Feffer, LifeSci Advisors
+ 1-212-915-2568
jeremy@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.